| # | Title | Journal | Year | Citations |
|---|
| 1 | Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship | Mayo Clinic Proceedings | 2008 | 2,424 |
| 2 | Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship | Mayo Clinic Proceedings | 2008 | 1,906 |
| 3 | Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. | Journal of Experimental Medicine | 1994 | 1,020 |
| 4 | Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients | Biology of Blood and Marrow Transplantation | 2005 | 745 |
| 5 | Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma | Blood | 2007 | 669 |
| 6 | Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2012 | 647 |
| 7 | Aspergillosis | New England Journal of Medicine | 2009 | 640 |
| 8 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial | Lancet Oncology, The | 2019 | 594 |
| 9 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Blood | 2015 | 586 |
| 10 | Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders | JAMA Oncology | 2016 | 534 |
| 11 | Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth | PLoS Computational Biology | 2014 | 419 |
| 12 | Small Cell Lung Cancer | Mayo Clinic Proceedings | 2008 | 412 |
| 13 | Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study | Journal of Clinical Oncology | 2006 | 400 |
| 14 | Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria | Clinical Infectious Diseases | 2008 | 368 |
| 15 | An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma | Annals of Oncology | 2011 | 361 |
| 16 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial | ESMO Open | 2020 | 343 |
| 17 | The clinical development of MEK inhibitors | Nature Reviews Clinical Oncology | 2014 | 342 |
| 18 | Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction | Cancer Cell | 2015 | 299 |
| 19 | Signal transducer and activator of transcription proteins in leukemias | Blood | 2003 | 296 |
| 20 | Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma | Clinical Cancer Research | 2017 | 288 |
| 21 | Expression and mutational analysis of MET in human solid cancers | Genes Chromosomes and Cancer | 2008 | 282 |
| 22 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer | Nature Genetics | 2011 | 279 |
| 23 | Novel Agents on the Horizon for Cancer Therapy | Ca-A Cancer Journal for Clinicians | 2009 | 275 |
| 24 | Understanding, recognizing, and managing toxicities of targeted anticancer therapies | Ca-A Cancer Journal for Clinicians | 2013 | 274 |
| 25 | Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial | Cancer | 1995 | 273 |
| 26 | In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents | Antimicrobial Agents and Chemotherapy | 2007 | 265 |
| 27 | Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data | Lancet Oncology, The | 2014 | 256 |
| 28 | Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo | British Journal of Haematology | 2008 | 235 |
| 29 | Nuclear or cytoplasmic expression of survivin: What is the significance? | International Journal of Cancer | 2005 | 225 |
| 30 | Comprehensive review on the HSC70 functions, interactions with related molecules and involvement in clinical diseases and therapeutic potential | International Journal of Cancer | 2012 | 224 |
| 31 | Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation | Nature | 1976 | 221 |
| 32 | Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator | Clinical Cancer Research | 2005 | 218 |
| 33 | Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma | Cancer | 2010 | 217 |
| 34 | New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) | Leukemia | 2014 | 214 |
| 35 | Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both GlobalCD20Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels | Clinical Cancer Research | 2008 | 213 |
| 36 | Identification of Myeloid Cell Subsets in Murine Lungs Using Flow Cytometry | American Journal of Respiratory Cell and Molecular Biology | 2013 | 212 |
| 37 | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States | Blood | 2017 | 210 |
| 38 | Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025 | European Urology | 2017 | 209 |
| 39 | Smoking at diagnosis and survival in cancer patients | International Journal of Cancer | 2013 | 206 |
| 40 | Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure | Seminars in Oncology | 1992 | 205 |
| 41 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial | Cancer | 2020 | 201 |
| 42 | Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis | Cancer | 2006 | 200 |
| 43 | Peroxiredoxin 1 Stimulates Secretion of Proinflammatory Cytokines by Binding to TLR4 | Journal of Immunology | 2010 | 191 |
| 44 | Morbidity and Mortality Associated with Gastrectomy for Gastric Cancer | Annals of Surgical Oncology | 2014 | 191 |
| 45 | Outcomes of sarcomatoid carcinoma of the lung: A Surveillance, Epidemiology, and End Results database analysis | Surgery | 2012 | 189 |
| 46 | Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer | Cancer | 1989 | 187 |
| 47 | Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents | Journal of Clinical Oncology | 2010 | 186 |
| 48 | Evolution of acute myelogenous leukemia stem cell properties after treatment and progression | Blood | 2016 | 179 |
| 49 | Treatment of Relapsed/Refractory Acute Myeloid Leukemia | Current Treatment Options in Oncology | 2017 | 179 |
| 50 | Hyperleukocytosis, leukostasis and leukapheresis: Practice management | Blood Reviews | 2012 | 177 |
